# Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms

> **NCT07664696** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Kimera Labs Inc.** · enrollment: 64 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** IV infusion using an isolated, placental, mesenchymal stem cell derived EVs
- **BIOLOGICAL:** Placebo IV administration

## Key facts

- **NCT ID:** NCT07664696
- **Lead sponsor:** Kimera Labs Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01
- **Primary completion:** 2028-06
- **Final completion:** 2028-12
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07664696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07664696, "Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07664696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*